Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.53 |
| ▸ | ATR | Q13535 | 6/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.53 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213821 | 1.00 | PIK3CB (0.58) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL5213813 | 1.00 | PIK3CB (0.58) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6625790 | 1.00 | PIK3CB (0.58) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6625795 | 1.00 | PIK3CB (0.58) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6626074 | 0.94 | PIK3CB (0.53) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6625597 | 0.94 | PIK3CB (0.53) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6625592 | 0.94 | PIK3CB (0.53) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6625589 | 0.94 | PIK3CB (0.53) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6626063 | 0.94 | PIK3CB (0.53) | PIK3CBLCKPDCD1CD274ATR | |
| SCHEMBL6626512 | 0.92 | PIK3CB (0.58) | PIK3CBLCKPDCD1CD274ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1557415-B1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-7307077-B2 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1389617-B1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-7153853-B2 | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20060009440-A1 | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1557415-A1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1020462-B1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-6251900-B1 | Heterocyclic compounds and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1020462-A1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009440-A1 | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | NCOR1, NR0B1, HCAR3 | PIK3CB 2950/4885LCK 3279/4885PDCD1 2629/4885 |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | CBR3, HCCS, CBR1 | PIK3CB 3376/4885LCK 1651/4885PDCD1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.